Yiwen Shi, MD
Neurology · Cherry Hill, NJNPI 1417452392
Payments from drug & device makers
What this record shows
This record is dominated by grants: $20,000 of the $26,189 with a category attached, or 76.4%. Medtronic accounts for 80.7% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2022 at $20,738 and has fallen 93.0% since, to $1,454 in 2025.
Across 132 payments — averaging $198.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$21K
- Boston Scientific$2K
- Amneal Pharmaceuticals LLC$771
- Supernus Pharmaceuticals, Inc.$280
- UCB, Inc.$228
- AbbVie$211
- plus $2K from 24 others
What the payments were for
- Consulting fees$7383%
- Grants$20,00076%
- Travel & lodging$2,1918%
- Food & beverage$3,26012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 17 | $21,134 |
| Boston Scientific | 11 | $2,041 |
| Amneal Pharmaceuticals LLC | 3 | $771 |
| Supernus Pharmaceuticals, Inc. | 2 | $280 |
| UCB, Inc. | 17 | $228 |
| AbbVie | 13 | $211 |
| Neurocrine Biosciences, Inc. | 9 | $171 |
| Cala Health, Inc. | 1 | $147 |
| Biogen | 6 | $133 |
| Amgen | 1 | $124 |
| Argenx US, Inc. | 5 | $87 |
| SK Life Science, Inc. | 4 | $83 |
| Teva Pharmaceuticals USA, Inc. | 5 | $79 |
| MDD US Operations, LLC | 2 | $78 |
| CSL Behring | 4 | $74 |
| Acadia Pharmaceuticals Inc | 4 | $70 |
| AstraZeneca(2 entities) | 4 | $69 |
| Lundbeck LLC | 4 | $65 |
| Merz Pharmaceuticals, LLC | 3 | $65 |
| Aucta Pharmaceuticals, Inc. | 5 | $56 |
| Genentech USA, Inc. | 2 | $39 |
| Neurelis, Inc. | 2 | $36 |
| Johnson & Johnson | 1 | $36 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Impel Pharmaceuticals LLC | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIVA PC$20,000
- VERCISE$1,243
- PERCEPT PC BRAINSENSE$737
- CALA KIQ$147
- CALA TRIO$147
How this compares
$26,189 in reported general payments places this provider in the 85th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 49 | $2,785 |
| Propranolol Hcl | 33 | $1,023 |
| Propranolol Hcl ErPropranolol Hcl | 20 | $613 |
| Primidone | 11 | $574 |
| Donepezil Hcl | 19 | $157 |
| Levetiracetam | 13 | $133 |
Paid to pharmacies, not to this prescriber.
Other neurology in Cherry Hill
- Keith PreisCherry Hill$36K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
- Mario VukicHackensack$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.